Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Labo Euromedis's FCF Yield % or its related term are showing as below:
During the past 13 years, the highest FCF Yield % of Labo Euromedis was 124.42%. The lowest was -17.57%. And the median was -1.12%.
FRA:61R's FCF Yield % is not ranked *
in the Medical Distribution industry.
Industry Median: 2.45 * Ranked among companies with meaningful FCF Yield % only.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Labo Euromedis FCF Yield % Related Terms
Labo Euromedis FCF Yield % Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Labo Euromedis's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis FCF Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labo Euromedis (FRA:61R) has a FCF Yield % of 0.00 as of Jul. 13, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Labo Euromedis and its competitors. According to the industry distribution chart, Labo Euromedis ranks #999999 out of 116 companies in the Medical Distribution industry.
Is Labo Euromedis' FCF Yield % too high?
Labo Euromedis' current FCF Yield % is 0.00. Based on the distribution chart, Labo Euromedis ranks #999999 out of 116 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Labo Euromedis has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' FCF Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #999999 out of 116 companies for FCF Yield %. This places Labo Euromedis in the lower half of its industry. The industry median FCF Yield % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Distribution company?
The median FCF Yield % among Medical Distribution companies is 2.45, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Labo Euromedis and its competitors. For the Medical Distribution industry, the median FCF Yield % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current FCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current FCF Yield % of 0.00. The stock's GF Value™ is €4.37, compared to a current price of €4.76 — trading 8.9% above its estimated fair value. The current FCF Yield % is 0.00. Labo Euromedis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current FCF Yield % is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (FRA:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.76 is trading 8.9% above its estimated GF Value™ of €4.37.
Key valuation signals for FRA:61R:
FCF Yield %: 0.00
GF Value™: €4.37 vs. price of €4.76 (8.9% above fair value)
No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
61GF Score
Get the complete analysis for FRA:61R
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61R has been successfully added to your 
